Financial Performance - First Half 2025 - Deliveries decreased by 43% year-over-year, from 4,904 units in 1H2024 to 2,813 units in 1H2025 [13] - Revenues decreased by 45% year-over-year, from $398 million in 1H2024 to $218 million in 1H2025 [13] - Gross profit decreased by 65% year-over-year, from $51 million in 1H2024 to $18 million in 1H2025 [13] - Gross profit margin decreased from 13% in 1H2024 to 8% in 1H2025 [13] - Operating loss decreased by 40% year-over-year, from $(438) million in 1H2024 to $(263) million in 1H2025 [13] - Net loss decreased by 32% year-over-year, from $(460) million in 1H2024 to $(313) million in 1H2025 [13] - Adjusted EBITDA decreased by 37% year-over-year, from $(382) million in 1H2024 to $(240) million in 1H2025 [13] Financial Performance - Second Quarter 2025 - Revenues decreased by 44% year-over-year, from $225 million in 2Q2024 to $126 million in 2Q2025 [13] - Gross profit decreased by 67% year-over-year, from $21 million in 2Q2024 to $7 million in 2Q2025 [13] - Operating loss decreased by 22% year-over-year, from $(204) million in 2Q2024 to $(160) million in 2Q2025 [13] - Net loss decreased by 36% year-over-year, from $(202) million in 2Q2024 to $(130) million in 2Q2025 [13] - Adjusted EBITDA decreased by 42% year-over-year, from $(177) million in 2Q2024 to $(103) million in 2Q2025 [13]

Financial Performance - Total revenue increased by 2% year-over-year to RMB 247,652 million[11], compared to RMB 243,236 million in the same quarter of the previous year[11] - Net income significantly increased by 76% to RMB 42,382 million[11], compared to RMB 24,022 million in the same quarter of the previous year[11] - Adjusted EBITA decreased by 14% year-over-year to RMB 38,844 million[11], compared to RMB 45,035 million in the same quarter of the previous year[11] - Non-GAAP net income decreased by 18% year-over-year to RMB 33,510 million[11], compared to RMB 40,691 million in the same quarter of the previous year[11] - Free cash flow turned negative, reaching RMB -18,815 million[14], compared to RMB 17,372 million in the same quarter of the previous year[14] Segment Performance - Alibaba China E-commerce Group revenue increased by 10% year-over-year[7] - Alibaba International Digital Commerce Group (AIDC) revenue increased by 19% year-over-year[7] - Cloud Intelligence Group revenue increased by 26% year-over-year[7] - Revenue from All others segment decreased by 28% year-over-year[26] Share Repurchase - The company repurchased 56 million ordinary shares (equivalent to 7 million ADSs) for a total of US$815 million during the quarter[17]

For personal use only FY25 : RESULTS PRESENTATION | August 29 2025 N B C U N I V E R S A L M E D I A P A R T N E R S H I P & F Y 2 0 R E S U L T S P R E S E N T A T I O N │ A U G U S T 2 0 2 0 FY25 RESULTS PRESENTATION AUG 2025 IMPORTANT NOTICE AND DISCLAIMER This document and any oral presentation accompanying it has been prepared in good faith, however, no express or implied representation or warranty is given as to the accuracy or completeness of the information in this document, in any accompanying pres ...

Financial Performance - Pro-forma revenue reached $19435 million, a decrease of 15% compared to FY24[15] - Pro-forma gross margin was 465%, a slight increase of 3 bps compared to FY24[15] - Pro-forma NPAT was $804 million, down 84% compared to the previous corresponding period[15] - Statutory NPAT was $281 million, including significant items of $523 million post-tax[17] - Net debt stood at $3648 million, an increase of 82% compared to FY24[15] - Cash conversion rate improved to 818%, compared to 769% in the previous corresponding period[15] Strategic Initiatives - The company closed or relocated 70 sites, including consolidating 23 smaller warehouses[17, 18] - The company opened 21 new branches and stores[17, 18] - $47 million of inventory was centralized as part of the supply chain consolidation[28] - The Autobarn loyalty program was strengthened, adding 500,000 new members, bringing the total to 17 million[29, 30]

Financial Performance - Austal achieved FY25 revenue of A$1.8 billion, a 24.1% increase compared to A$1.5 billion in FY24 [2, 7] - The company's EBIT doubled to A$113.4 million in FY25, representing a 100.8% increase from A$56.5 million in FY24 [2, 7] - Austal's order book reached A$13.1 billion, a 2.9% increase from A$12.7 billion in FY24 [2, 7] - Operating cashflow significantly improved to A$406.3 million, a substantial increase of A$419.3 million compared to A$(13.0) million in FY24 [7] - Statutory NPAT increased by 503.2% from A$14.9 million to A$89.7 million [7, 15] Operational Highlights - Austal USA was awarded a US$450 million contract to expand submarine module manufacturing [8] - The company signed a Strategic Shipbuilding Agreement (SSA) with the Commonwealth of Australia [7, 8, 31] - Austal delivered 7 ships and had 49 ships under construction or scheduled in FY25 [2] - Austal Philippines delivered the 32-meter 'Ocean Master' catamaran to Rottnest Fast Ferries [8, 41] Strategic Initiatives - Austal is investing up to A$1.2 billion in facility expansions, including Final Assembly 2 (FA2) and Module Manufacturing 3 (MMF3) projects in Mobile, Alabama [29, 54] - The company is targeting $500 million in Through Life Support revenue by FY27 [42]

For personal use only Disclaimer and important information Disclaimer and important notice This presentation has been prepared by McMillan Shakespeare Limited ABN 74 107 233 983 ("MMS"). It contains summary information about MMS and its subsidiaries and their activities current as at the date of this presentation. The presentation contains selected information and does not purport to be all inclusive or to contain information that may be relevant to a prospective investor. No reliance may be placed on MMS f ...

FITZROY ISLAND | CAIRNS | AUSTRALIA DISCLAIMER Summary information FY25 RESULTS PRESENTATION For personal use only EXPERIENCE CO LIMITED | FY25 RESULTS | AUGUST 2025 This presentation has been prepared by Experience Co Limited (ASX: EXP) contains summary information about EXP and its related bodies corporate and their activities. The information in this presentation is of a general background nature and does not purport to be complete or comprise all the information that an investor would require when makin ...

Financial Performance - MOVE Logistics Group's FY25 revenue was NZD 286.3 million [58] - Normalised Earnings Before Tax (NEBT) improved by 61.1% year-over-year [17, 28], representing a NZD 15.7 million increase [59] - Gross Margin increased by 13.4% to NZD 83.5 million [18, 25], with Gross Margin percentage up by 4.1 percentage points to 29.2% [18, 26] - Net Loss After Tax (NLAT) improved by NZD 32.5 million [59] to NZD -15.6 million [58] Transformation Programme & Cost Reduction - The "Accelerate Transformation Programme" delivered approximately NZD 27 million in cost reductions in FY25 [22, 60] - People costs decreased by approximately NZD 15 million [62] - Transport costs, as a percentage of Freight revenue, decreased by 5.1 percentage points [62] Business Segment Performance - Freight and Fuel segment revenue was NZD 188.8 million [35, 36], with a 90% improvement in NEBT loss [21, 39] - Specialist segment revenue increased to NZD 18.2 million [47, 48], with Normalised EBT at NZD 2.3 million [47, 49] - International segment revenue increased to NZD 25.7 million [53, 54], with Normalised EBT at NZD 0.3 million [53, 55] Future Outlook - The company is targeting a return to positive normalised EBT in FY26 [80]

Financial Performance - Revenue from cell therapy products reached US$172 million, a 191% increase compared to the previous year[30] - Ryoncil's successful launch contributed US$132 million in gross sales and US$113 million in reported net sales after a 146% gross to net adjustment[30] - Net operating cash spend was US$50 million, a 3% increase on prior year[30] - Cash on hand at June 30, 2025, was US$162 million (A$247 million)[30] Ryoncil (remestemcel-L) - Ryoncil became the first FDA-approved MSC product in the US in December 2024 and commercially available on March 28, 2025[24] - The company onboarded 32 US transplant centers, aiming for the top 45 centers (80% of pediatric bone marrow transplants) by the end of the quarter[24] - Ryoncil demonstrated a 70% overall response rate at Day 28 in a Phase 3 trial for SR-aGvHD[41,43] - In children from GVHD001 trial, 49% survival at Year 4, with only 14% (N=7) died due to aGvHD through 4 years[44] Market Opportunities - Steroid-refractory acute GvHD for children & adults represents a ~US$1 billion market[21] - Biologic-refractory inflammatory bowel disease represents a >US$5 billion market[21] - Heart failure with reduced ejection fraction (HFrEF) represents a >US$10 billion market[21] - Chronic low back pain (CLBP) represents a >US$10 billion market[21]

Financial Performance - Operating revenue decreased by 3.4% from $24.75 million in FY24 to $23.90 million in FY25[13, 15] - MetroMap subscription revenue increased by 11.5% to $9.57 million in FY25[12, 14, 18, 65, 68] - Subscription revenue now contributes 40% of total revenue[12, 65] - MetroMap Annual Contract Value (ACV) grew by 12.8% to $10.56 million[13, 14, 16, 18, 65, 69] - 3D revenue increased significantly by 78.4% to $1.53 million[14, 29, 65] - LiDAR revenue decreased by 22.8% to $10.92 million[25, 65] - EBITDA increased by 19.8% from $2.89 million in FY24 to $3.46 million in FY25[13, 68, 70] Strategic Focus - The company is focused on scaling revenue and driving cash generation[66] - Key focus areas for FY26 include driving ACV and off-the-shelf sales for MetroMap, building the MetroMap Program Partner model, and product enhancements[57, 61] - The company aims to build and accelerate the opportunity pipeline for LiDAR and explore new market opportunities in renewables and carbon farming[58, 61] - For Global 3D, the company plans to pursue Australian project opportunities and continue to build awareness and capability in international markets[59, 61]